The vaginal microbiota of women living with HIV on suppressive antiretroviral therapy and its relation to high-risk human papillomavirus infection

Table 2 High-Risk HPV infection and cervical cytology

	All	SNW	WLWH	P value
Number	83	39	44
HPV infection
Positive	26 (31.33)	13 (33.33)	13 (29.55)	0.813
Negative	57 (68.67)	26 (66.67)	31 (70.45)	0.813
HR-HPV genotypes^a
HPV16	1 (3.85)	1 (7.69)	0 (0)	0.367
HPV16 and others HR-HPV	1 (3.85)	0 (0)	1 (7.69)
Others hrHPV	24 (92.31)	12 (92.31)	12 (92.31)
Cervical cytology^b
NILM	66 (90.41)	30 (88.24)	36 (92.31)	0.697
Abnormal cervical cytology	7 (9.59)	4 (11.76)	3 (7.69)
Type of abnormal cytology^b
LSIL	5 (6.85)	4 (11.76)	1 (2.56)
HSIL	2 (2.74)	0 (0)	2 (5.13)
HPV vaccine^c
NO	43 (89.58)	29 (93.55)	14 (82.35)	0.330
YES	5 (10.42)	2 (6.45)	3 (17.65)	0.330

Data are expressed as n (%). Fisher's exact test was used to compare categorical variables
Abbreviations: HPV Human Papillomavirus, HSIL High-grade squamous intraepithelial lesions, HR-HPV High Risk Human Papillomavirus, LSIL Low-grade squamous intraepithelial lesions, NILM Negative for intraepithelial lesion or malignancy, SNW Seronegative women, WLWH Women living with HIV
^aHPV detection assay can detect 14 high risk HPV genotypes: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 and partially genotype 16, 18 from other 12 high risk genotypes. Others HR-HPV refers to the 12 HR-HPV detected by the assay
^bCytology screening was reported according to the Bethesda system. Cervical cytology results were only available for 73 women (34 SNW and 39 WLWH). Frequencies of LSIL and HSIL were calculated overall (All, n = 83, SNW, n = 39 and WLWH, n = 44 and not within women with abnormal cytology)
^cData on HPV vaccination were missing in 35 women (8 SNW and 27 WLWL)

ISSN: 1471-2180